NTNorifumi Tsukamoto

Norifumi Tsukamoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Norifumi Tsukamoto has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrin α7 and Extracellular Matrix Laminin 211 Interaction Promotes Proliferation of Acute Myeloid Leukemia Cells and Is Associated with Granulocytic Sarcoma

    by Nobuhiko Kobayashi, Tsukasa Oda, Makiko Takizawa, Takuma Ishizaki, Norifumi Tsukamoto, Akihiko Yokohama, Hisashi Takei, Takayuki Saitoh, Hiroaki Shimizu, Kazuki Honma, et al.

    Acute myeloid leukemia (AML) with granulocytic sarcoma (GS) is characterized by poor prognosis; however, its underlying mechanism is unclear. Bone marrow samples from 64 AML patients (9 with GS and 55 without GS) together with AML cell lines PL21, THP1, HL60, Kasumi-1, and KG-1 were used to elucidate the pathology of AML with GS. RNA-Seq analyses were performed on samples from seven AML patients with or without GS. Gene set enrichment analyses revealed significantly upregulated candidates on the cell surface of the GS group. Expression of the adhesion integrin α7 (ITGA7) was significantly higher in the GS group, as seen by RT-qPCR (p = 0.00188) and immunohistochemistry of bone marrow formalin-fixed, paraffin-embedded (FFPE) specimens. Flow cytometry revealed enhanced proliferation of PL21 and THP1 cells containing surface ITGA7 in the presence of laminin 211 and stimulated ERK phosphorylation; this effect was abrogated following ITGA7 knockdown or ERK inhibition. Overall, high ITGA7 expression was associated with poor patient survival (p = 0.0477). In summary, ITGA7 is highly expressed in AML with GS, and its ligand (laminin 211) stimulates cell proliferation through ERK signaling. This is the first study demonstrating the role of integrin α7 and extracellular matrix interactions in AML cell proliferation and extramedullary disease development.


  • Open Access

    IgG4-related Disease with a Cardiac Mass

    by Ikuko Matsumura, Takeki Mitsui, Kenichi Tahara, Hiroaki Shimizu, Kunio Yanagisawa, Takuma Ishizaki, Hiromi Koiso, Makiko Takizawa, Akihiko Yokohama, Takayuki Saitoh, et al.

    A 69-year-old man with palpitations and decreased blood pressure was referred. Echocardiography showed a mass in the right atrium and cardiac septum. The serum IgG4 level was 1,450 mg/dL. A biopsy of the cardiac mass showed fibrosis with inflammatory cells and increased IgG4-positive plasma cells and lymphocytes. Flow cytometry and polymerase chain reaction of the immunoglobulin heavy chain did not demonstrate monoclonality. He was diagnosed with IgG4-related disease (IgG4-RD). IgG4-RD with a cardiac mass is rare and it is difficult to distinguish it from malignant lymphoma by a pathological examination alone. We therefore performed a biopsy and analyzed the clonality in order to make an accurate diagnosis of IgG4-RD.


  • Prognostic impact of trisomy 21 in follicular lymphoma

    by Takeki Mitsui, Akihiko Yokohama, Hiromi Koiso, Akio Saito, Kohtaro Toyama, Hiroaki Shimizu, Takuma Ishizaki, Hiroyuki Irisawa, Makiko Takizawa, Takayuki Saitoh, et al.

    Summary: The chromosomal abnormalities associated with follicular lymphoma (FL) prognosis are not fully elucidated. Here, we evaluated the pattern of chromosomal abnormalities in FL, and clarified the correlations between the cytogenetic features and clinical outcome. Cytogenetic analysis was performed using standard methods of Giemsa‐banding at diagnosis for 201 FL patients admitted to our hospitals between 2001 and 2013. The identified chromosomal abnormalities were: t(14;18)(q32;q21) (59·2%), +X (17·9%), del(6)(q)/‐6 (16·9%), +7 (14·4%), abnormality of 1q12‐21/1q (12·9%), del(13)(q)/‐13 (11·9%), abnormality of 3q27 (10·4%), abnormality of 10q22‐24 (10·0%), +12/dup(12)(q) (10·0%), abnormality of 1p21‐22/1p (9·0%), +18 (9·0%), del(17)(p)/‐17 (5·0%), and a complex karyotype (54·7%). Patients with trisomy 21 had a significantly shorter progression‐free survival (P = 0·00171) and overall survival (OS) (P < 0·001) than those without trisomy 21; additionally, patients with trisomy 21 in the rituximab‐treated cohort also had a significantly shorter OS (P = 0·000428). Multivariate analysis identified trisomy 21 as an independent risk factor in our cohorts with or without t(14;18) (P = 0·015). In conclusion, the presence of trisomy 21 was an independent risk factor for in FL. Chromosomal analysis of FL patients at diagnosis can provide useful information about their expected survival.


  • Tumor long-axis diameter and SUVmax predict long-term responders in 90Y-ibritumomab tiuxetan monotherapy

    by Norifumi Tsukamoto, Akihiko Yokohama, Tetsuya Higuchi, Takeki Mitsui, Hiromi Koiso, Makiko Takizawa, Hiroaki Shimizu, Takuma Ishizaki, Morio Matsumoto, Kohtaro Toyama, et al.

    90Y-ibritumomab tiuxetan (90Y-IT) is widely used, but the factors responsible for its optimal treatment effects are unknown. We enrolled 34 patients with relapsed indolent lymphoma treated with 90Y-IT monotherapy at Gunma University Hospital between 2003 and 2014 in the present study. Clinical data including computed tomography and 18-Fluoro-deoxyglucose positron emission tomography were retrospectively analyzed. The overall response rate and complete response rate were 91% and 82%, respectively. The median progression-free survival (PFS) and overall survival were 32 months and not reached, respectively. In univariate analysis, tumor long-axis diameter ≤ 2.5 cm, maximum standardized uptake value (SUVmax) ≤ 6.5, localized disease, normal levels of serum soluble interleukin-2 receptor, and the number of involved nodal sites ≤ 3 immediately prior to 90Y-IT were associated with median PFS greater than 6 years. However, in multivariate analysis, only tumor long-axis diameter ≤ 2.5 cm and SUVmax ≤ 6.5 affected PFS [hazard ratio (HR) 0.130, P = 0.0021 and HR 0.283, P = 0.0311, respectively]. Patients with only one prior regimen needed less granulocyte colony-stimulating factor and platelet transfusion. Thus, 90Y-IT treatment should be considered for patients with indolent lymphoma in first relapse who have tumor long-axis diameter ≤ 2.5 cm and SUVmax ≤ 6.5.


  • Efficacy and Safety of Intermediate dose Etoposide for Mobilization of Peripheral Blood Stem Cells in Hematopoietic Tumors

    by Takuma Ishizaki, Akihiko Yokohama, Hiroaki Shimizu, Kunio Yanagisawa, Yoshiyuki Ogawa, Takeki Mitsui, Hiromi Koiso, Makiko Takizawa, Takayuki Saitoh, Hirokazu Murakami, et al.

    再発難治悪性リンパ腫や若年者症候性多発性骨髄腫に対し,自家末梢血幹細胞移植が標準治療として行われている.移植後の速やかな生着には2.0×106/kgのCD34陽性細胞が必要とされ,末梢血幹細胞採取効率の向上が期待される.当科で2000年12月から2015年3月までに末梢血幹細胞採取(Peripheral blood stem cell harvest: PBSCH)を行った悪性リンパ腫と多発性骨髄腫の82例のうち,動員化学療法としてetoposide中等量療法(350 mg/m2,4日間)を施行した19例を対象として,その有効性と安全性を検討した.15例(79%)で必要量のCD34陽性細胞の採取を達成した.白血球数1000/μl以下の期間中央値は5日間(3日~7日)で,37.5度以上の発熱は解析可能な13例中9例に認め,菌血症の1例以外は発熱性好中球減少症で,全例抗菌薬治療が奏効した.Grade 3の口腔粘膜炎を1例に認めたが,それ以外に重篤な有害事象はなかった.Etoposide中等量療法は有効で安全な動員化学療法と考えられた.

  • Open Access

    The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP

    by Noriyuki Takahashi, Takayuki Saitoh, Nanami Gotoh, Yasuhiro Nitta, Lobna Alkebsi, Tetsuhiro Kasamatsu, Yusuke Minato, Akihiko Yokohama, Norifumi Tsukamoto, Hiroshi Handa, et al.

    T-helper cell type 1 (Th1) polarization in chronic immune thrombocytopenia (cITP) has been reported at the protein and mRNA levels. We evaluated the impact of Th1/Th2 cytokine and cytokine receptor functional polymorphisms on both susceptibility to, and severity of, cITP. We analysed IFN-γ + 874 T/A, IFN-γR -611G/A, IL-4 -590C/T, and IL-4Rα Q576R polymorphisms in 126 cITP patients (male/female: 34/92; median age: 47.7 years) and 202 healthy control donors. Genotyping was determined by PCR and direct sequencing. The Th1/Th2 ratio was detected in peripheral blood mononuclear cells via flow cytometry. cITP patients had a higher frequency of the IL-4Rα 576 non-QQ genotype compared to healthy subjects (P = 0.04). cITP patients with the IFN-γ +874 non-AA genotype (high expression type) showed more severe thrombocytopenia than those with the AA genotype (P < 0.05). cITP patients had a significantly higher Th1/Th2 ratio than control patients (P < 0.01); this ratio was inversely correlated with platelet counts. Furthermore, patients with both IFN-γ +874 non-AA genotype (high expression type) and IFN-γR −611 non-AA genotype (high-function type) had a significantly higher Th1/Th2 ratio (P < 0.05). The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP.


  • Mutation of the SF3B1 predict a poor prognosis in japanese CLL patients

    by Takeki Mitsui, Hiromi Koiso, Hirotaka Namahashi, Akio Saito, Takuma Ishizaki, Makiko Taakizawa, Akihiko Yokohama, Takayuki Saito, Takahiro Jinbo, Hidemi Ogura, et al.

  • A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents

    by Hirono Iriuchishima, Takayuki Saitoh, Hiroshi Handa, Atsushi Isoda, Morio Matsumoto, Morio Sawamura, Atsushi Iwasaki, Chiaki Ushie, Hikaru Hattori, Yoshiko Sasaki, et al.

    Various prognostic markers for multiple myeloma (MM) have been identified, and stratification using these markers is considered important to optimize treatment strategies. The international staging system (ISS) is now a widely accepted prognostic staging system for MM patients; however, its validity is controversial in the era of new therapeutic regimens, since ISS had been established before introduction of new agents. We retrospectively reviewed prognostic factors in order to seek out an alternative staging system more suitably applied to MM patients treated with novel agents. We analyzed 178 newly diagnosed MM patients who received either conventional chemotherapy without novel agents (CT; n = 79) or chemotherapy with novel agents (NT; n = 99). Although median overall survival (OS) of patients treated with CT is significantly different depending on stages of ISS, ISS had no effect on OS among patients treated with NT. Meanwhile, we identified hemoglobin (Hb) and plasmacytoma as independent risk factors for OS in patients who received NT. Using these two parameters, we stratified NT patients into three stages; stage 1 (Hb≥10 g/dL and absence of plasmacytoma), stage 2 (not stage 1 or 3), and stage 3 (Hb <10 g/dL and presence of plasmacytoma). We found that there were significant differences in median OS among the three stages (8.13, 5.95, and 2.45 yr for stages 1, 2, and 3, respectively). This preliminary study suggests that this alternative staging system based on Hb and plasmacytoma is a simple and useful way to predict prognosis of MM patients in the novel agent era.


    • 1 June 2014
      • Vol. 55  (6) , 687-91

    [Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment].

    by Makiko Takizawa, Akihiko Yokohama, Tomomi Sekigami, Hiromi Koiso, Takuma Ishizaki, Takeki Mitsui, Yoshiyuki Ogawa, Takayuki Saitoh, Hiroshi Handa, Norifumi Tsukamoto, et al.

    Herein, we report a patient with polycythemia vera (PV) who exhibited Philadelphia chromosome (Ph) positive CML-like clinical features after 13 years of hydroxycarbamide administration and successful treatment with a tyrosine kinase inhibitor (TKI). She was 64 years old when initially diagnosed with PV and was confirmed to be negative for BCR-ABL translocation. Thirteen years later, with increasing white blood cell and platelet counts, a BCR-ABL positive clone emerged and the JAK2V617F mutation disappeared. After TKI treatment, the BCR-ABL copy number decreased and the JAK2V617F mutation was again detected. Furthermore, MPN clinical features were observed. This case provides insights into the clonal divergence and growth advantage of the Ph positive clone over the MPN clone. Whether JAK2V617F is an MPN initiating event or a secondary mutation has been a point of discussion for the past several years. This issue is also considered in the present report.